GW Pharmaceuticals PLC- (GWPH) Receives “Overweight” Rating from Cantor Fitzgerald

Share on StockTwits

Cantor Fitzgerald reiterated their overweight rating on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in a research note published on Tuesday morning. Cantor Fitzgerald also issued estimates for GW Pharmaceuticals PLC-‘s FY2019 earnings at ($6.24) EPS.

Several other research firms have also commented on GWPH. Bank of America reissued a buy rating and set a $197.00 price target (up from $181.00) on shares of GW Pharmaceuticals PLC- in a research report on Friday, September 28th. Morgan Stanley boosted their price target on GW Pharmaceuticals PLC- from $197.00 to $240.00 and gave the stock an overweight rating in a research report on Friday, September 28th. BidaskClub raised GW Pharmaceuticals PLC- from a hold rating to a buy rating in a research report on Saturday, September 22nd. ValuEngine raised GW Pharmaceuticals PLC- from a buy rating to a strong-buy rating in a research report on Thursday, November 1st. Finally, Zacks Investment Research raised GW Pharmaceuticals PLC- from a hold rating to a strong-buy rating and set a $168.00 price target on the stock in a research report on Wednesday, October 10th. One analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. GW Pharmaceuticals PLC- presently has a consensus rating of Buy and an average price target of $185.38.

NASDAQ GWPH opened at $124.84 on Tuesday. GW Pharmaceuticals PLC- has a 1-year low of $105.12 and a 1-year high of $179.65. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.34 and a current ratio of 6.66.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its quarterly earnings results on Tuesday, November 27th. The biopharmaceutical company reported ($2.76) EPS for the quarter, missing the consensus estimate of ($2.48) by ($0.28). The company had revenue of $2.40 million for the quarter, compared to analyst estimates of $2.62 million. GW Pharmaceuticals PLC- had a negative return on equity of 50.93% and a negative net margin of 1,574.21%. The business’s revenue was down 4.0% on a year-over-year basis. During the same period last year, the firm posted ($0.14) earnings per share. As a group, sell-side analysts predict that GW Pharmaceuticals PLC- will post -9.24 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of GWPH. Janney Montgomery Scott LLC purchased a new stake in shares of GW Pharmaceuticals PLC- during the 2nd quarter worth approximately $236,000. BNP Paribas Arbitrage SA increased its stake in shares of GW Pharmaceuticals PLC- by 497.0% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 1,200 shares of the biopharmaceutical company’s stock worth $167,000 after purchasing an additional 999 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its stake in shares of GW Pharmaceuticals PLC- by 75.5% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 9,277 shares of the biopharmaceutical company’s stock worth $1,295,000 after purchasing an additional 3,990 shares during the last quarter. TD Asset Management Inc. increased its stake in shares of GW Pharmaceuticals PLC- by 36.5% during the 2nd quarter. TD Asset Management Inc. now owns 23,076 shares of the biopharmaceutical company’s stock worth $3,220,000 after purchasing an additional 6,176 shares during the last quarter. Finally, Commonwealth Equity Services LLC increased its stake in shares of GW Pharmaceuticals PLC- by 49.3% during the 2nd quarter. Commonwealth Equity Services LLC now owns 15,500 shares of the biopharmaceutical company’s stock worth $2,163,000 after purchasing an additional 5,117 shares during the last quarter. Institutional investors own 69.38% of the company’s stock.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.

Further Reading: Find a Trading Strategy That Works

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.